Clinical research - Press Releases

Date	Title	Company
14-Dec-2023	Families affected by ALS urged to join free program to uncover their genetic risk, contribute to research, and access new therapies	• Sano Genetics
14-Dec-2023	POLB 001 Data Presented at ASH	Poolbeg Pharma plc
14-Dec-2023	1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors	1ST Biotherapeutics
12-Dec-2023	NEW ANALYSES PRESENTED AT ASH 2023 SUPPORT THE POTENTIAL LONG-TERM RESPONSE AND SAFETY OF KITE’S TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) IN PATIENTS WITH AGGRESSIVE BLOOD CANCERS	KITE
12-Dec-2023	Scottish Medicines Consortium Accepts Libtayo®▼ (cemiplimab) as First Approved Drug Treatment for Advanced Cutaneous Squamous Cell Carcinoma in Scotland	Libtayo®▼
11-Dec-2023	POLB 001 – targeting Cytokine Release Syndrome (CRS) associated with cancer immunotherapies	Poolbeg Pharma plc
11-Dec-2023	NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222 at the 65th American Society of Hematology Annual Meeting	NovalGen
11-Dec-2023	New therapeutic target for rare type of childhood epilepsy	Francis Crick Institute
11-Dec-2023	ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023	ImmunOs Therapeutics
08-Dec-2023	Velocity Clinical Research expands to Poland	Velocity Clinical Research
08-Dec-2023	Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies	Sosei Heptares
06-Dec-2023	Rare disease patients are breaking down language and location barriers in a new online community	Sciensus
06-Dec-2023	Dr. Vijay Ivaturi Announced as New Chief Executive Officer at PumasAI	PumasAI
05-Dec-2023	Columbus makes offer to acquire CRO agency Endless Gain	Columbus
05-Dec-2023	Recipharm announces collaboration with Oz-UK to accelerate the development of low global warming potential pMDIs utilising HFA-152a propellant	Recipharm
05-Dec-2023	Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board	Thermosome GmbH
04-Dec-2023	Azalea Vision Announces First On-Eye test of ALMA, its Revolutionary	Azalea
04-Dec-2023	EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001	EBViously GmbH
30-Nov-2023	CellProthera expanding into ischemic stroke following publication of positive preclinical results with its CD34+ stem cell platform	CellProthera
30-Nov-2023	Columbus makes offer to acquire CRO agency Endless Gain	Columbus